Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates

Zheng, Biyuan; Yang, Xiaoqing; Zhao, Yang; Zheng, Qiao-Feng; Ke, Mei‐Rong; Lin, Tao; Chen, Renxun; Ho, Kaitlyn; Kumar, Naresh; Huang, Jian‐Dong

doi:10.1016/j.ejmech.2018.05.039

Cited by 30 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The IC 50 values were obtained between 0.2 and 100 μM for the silicon phthalocyanines. 75 Aru et al investigated the anticancer efficacy of a silicon phthalocyanine axially substituted with 3-hydroxypyridin-2-thione cells on breast cancer cell lines and a healthy human endothelial cell line. 76 The IC 50 values were determined between 9.2 and 42 μM.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Anticancer and biological properties of new axially disubstituted silicon phthalocyanines

Farajzadeh¹,

Kuşçulu²,

Yenilmez³

et al. 2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

“…Cells were incubated at 5% CO 2 in a 37 °C humidified incubator. 75,76 Cells were cultured in 75 cm 2 flasks.…”

Section: Methodsmentioning

confidence: 99%

Anticancer and biological properties of new axially disubstituted silicon phthalocyanines

Farajzadeh¹,

Kuşçulu²,

Yenilmez³

et al. 2022

Dalton Trans.

View full text Add to dashboard Cite

show abstract

“…Zheng et al explored two variables in the conjugate design for targeted PDT, i.e., linker length and number of peptides. 67 The click reaction was used to synthesize silicon phthalocyanines axially substituted with cyclic peptide, cRGD (29a−c, Figure 11). Different ethylene glycol units (n = 2−4; named a−c, respectively) were utilized as a linker between silicon phthalocyanines and the peptides to obtain conjugates with varied lengths and properties.…”

Section: Reducible Disulfide Linker Chemistrymentioning

confidence: 99%

“…Zheng et al. explored two variables in the conjugate design for targeted PDT, i.e., linker length and number of peptides . The click reaction was used to synthesize silicon phthalocyanines axially substituted with cyclic peptide, cRGD ( 29a – c , Figure ).…”

Section: Noncleavable Linker Chemistriesmentioning

confidence: 99%

Peptide–Drug Conjugates with Different Linkers for Cancer Therapy

2020

View full text Add to dashboard Cite

Drug conjugates are chemotherapeutic or cytotoxic agents covalently linked to targeting ligands such as an antibody or a peptide via a linker. While antibody–drug conjugates (ADCs) are now clinically established for cancer therapy, peptide–drug conjugates (PDCs) are gaining recognition as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment. The linker in a drug conjugate plays a key role in the circulation time of the conjugate and release of the drug for full activity at the target site. Herein, we highlight the main linker chemistries utilized in the design of PDCs and discuss representative examples of PDCs with different linker chemistries with the related outcome in cell and animal studies.

show abstract

“…Experiments were conducted using HT-29, a high integrin expressing human colon carcinoma cell line, and these demonstrated targeted phototoxicity. In vivo studies using mice with an H22 tumor, which is a high integrin expressing mouse hepatic carcinoma cell line, showed specific localization of the bioconjugate to the tumor under fluorescence and resulted in tumor growth inhibition [135]. Additional research has used a [N,C,N-Pt(II)] complex bearing a NˆCˆN 1,3-di(2-pyridyl)-benzene linked to a cRGD-tyrosine-lysine peptide to target rat bladder cancer cells [136], EtNBS (a Nile blue derivative) conjugated to cRGD and a PEG chain which showed specific phototoxicity in OVCAR-5 human ovarian cancer cells in vitro [137], and a zinc(II) phthalocyanine substituted with three 2,4-dinitrobenzenesulfonate groups and a cRGD-phenylalanine-lysine moiety that exhibited target phototoxicity to a high integrin expressing cell line MDA-MB-231 cells [138].…”

Section: Integrinsmentioning

confidence: 99%

Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer

Gómez

Tsung

2020

Molecules

View full text Add to dashboard Cite

Photodynamic diagnosis (PDD) and therapy (PDT) are emerging, non/minimally invasive techniques for cancer diagnosis and treatment. Both techniques require a photosensitizer and light to visualize or destroy cancer cells. However, a limitation of conventional, non-targeted PDT is poor selectivity, causing side effects. The bioconjugation of a photosensitizer to a tumor-targeting molecule, such as an antibody or a ligand peptide, is a way to improve selectivity. The bioconjugation strategy can generate a tumor-targeting photosensitizer conjugate specific for cancer cells, or ideally, for multiple tumor compartments to improve selectivity and efficacy, such as cancer stem cells and tumor neovasculature within the tumor microenvironment. If successful, such targeted photosensitizer conjugates can also be used for specific visualization and detection of cancer cells and/or tumor angiogenesis (an early event in tumorigenesis) with the hope of an early diagnosis of cancer. The purpose of this review is to summarize some current promising target molecules, e.g., tissue factor (also known as CD142), and the currently used bioconjugation strategies in PDT and PDD, with a focus on newly developed protein photosensitizers. These are genetically engineered photosensitizers, with the possibility of generating a fusion protein photosensitizer by recombinant DNA technology for both PDT and PDD without the need of chemical conjugation. We believe that providing an overview of promising targets and bioconjugation strategies will aid in driving research in this field forward towards more effective, less toxic, and non- or minimally invasive treatment and diagnosis options for cancer patients.

show abstract

Synthesis and photodynamic activities of integrin-targeting silicon(IV) phthalocyanine-cRGD conjugates

Cited by 30 publications

References 45 publications

Anticancer and biological properties of new axially disubstituted silicon phthalocyanines

Anticancer and biological properties of new axially disubstituted silicon phthalocyanines

Peptide–Drug Conjugates with Different Linkers for Cancer Therapy

Current Targets and Bioconjugation Strategies in Photodynamic Diagnosis and Therapy of Cancer

Contact Info

Product

Resources

About